Full metadata record
DC FieldValueLanguage
dc.contributor.author王雲銘en_US
dc.contributor.authorWang, Yun-Mingen_US
dc.date.accessioned2014-12-13T10:43:22Z-
dc.date.available2014-12-13T10:43:22Z-
dc.date.issued2011en_US
dc.identifier.govdoc1002001INER086zh_TW
dc.identifier.urihttp://hdl.handle.net/11536/99710-
dc.identifier.urihttps://www.grb.gov.tw/search/planDetail?id=2281659&docId=358676en_US
dc.description.abstract根據衛生署的統計,國人十大死亡原因中,慢性肝病、肝硬化為第六位,而肝癌更是國內十大癌症死亡原因的第一位,若能早期診斷,應有助於預防肝癌的發生。新近文獻報導聚合型半乳胺醣胜肽對肝細胞有特異性之結合。本計劃預計建立可用於診斷肝癌之醣質氧化鐵藥物之動物造影技術平台,將聚合型半乳胺醣胜肽和超順磁氧化鐵奈米粒子結合後,利用肝癌鼠動物模式,藉由磁振造影結果評估該醣質氧化鐵對比劑作為肝癌早期診斷工具之可行性。zh_TW
dc.description.abstractAsialoglycoprotein receptors(ASGP-R), situated on the hepatocyte membrane, can recognize galactose or N-acetylgalactosamine terminal of desialylated glycoprotein or glycopeptide. Sawamura et al. reported that a decrease in the number of ASGP-R led to an accumulation of asialoglycoprotein in the sera of galactosamine-treated rats, and the number of these receptors decreases in patients with chronic liver diseases. In this study, the hepatoma animal model will be established by treating the animal with proper chemicals. Glyco-drug will be used to evaluate its potential for diagnosis of liver disease with MRI technique.en_US
dc.description.sponsorship行政院原子能委員會zh_TW
dc.language.isozh_TWen_US
dc.subject磁振造影對比劑zh_TW
dc.subject聚合型半乳醣胺胜?zh_TW
dc.title醣質肝膽磁振造影劑之研究zh_TW
dc.titleApplication Research of Glyco MRI Contrast Agenten_US
dc.typePlanen_US
dc.contributor.department國立交通大學生物科技學系zh_TW
Appears in Collections:Research Plans